Grifols Q1 revenue misses consensus, net profit jumps

Grifols reported Q1 revenue of €1.7 billion, up 3.3% on a constant currency basis but slightly below the €1.72 billion consensus, and net profit rose 21.9% year over year to €73 million. Adjusted EBITDA increased to €381 million with margins stable at 22.4%, while Biopharma revenue rose 6.8% and immunoglobulin sales grew 15.3% on strong demand for Gamunex and the launch of Yimmugo. Offsetting that strength, albumin revenue fell 6.1% on ongoing pricing pressure in China, and shares were down 0.8%.

Analysis

GRFS is signaling a quality-of-earnings story more than a growth breakout: the mix is improving toward higher-margin biologics while the weak spot remains a price-regulated commodity exposure. That matters because the market typically rewards this setup only when the higher-value franchise can offset pricing drag for multiple quarters, not just one print. The fact that margins stayed stable despite the revenue miss suggests operating discipline, but it also implies limited room for further upside unless volume acceleration broadens beyond the current product leaders.

The second-order read-through is competitive: sustained IVIG strength plus a fresh U.S. launch raises the pressure on mid-cap plasma peers that lack either scale or a differentiated label portfolio. If the new product can take share without a major discount, it improves the odds that the segment’s growth rate stays above the broader specialty-proteins market over the next 2-4 quarters. The weak albumin environment, however, warns that China-linked pricing can still blunt the overall story and cap multiple expansion until that channel stabilizes.

Catalyst-wise, this is a stock that can work on operating momentum over 1-3 months, but leverage leaves it vulnerable to any disappointment in cash conversion or working capital reversal. The key risk is that the current quarter may be as good as it gets if replenishment demand normalizes and pricing pressure persists in China. In that case, the name likely trades as a stable but not re-rating asset: good downside support, limited upside unless management guides to sustained biopharma mix shift and FCF inflection.

Key Decisions for Investors

• Stay modestly long GRFS into the next earnings cycle, but size it as a quality-balance-sheet recovery rather than a high-conviction growth name; target 3-6 months, with upside contingent on continued Biopharma mix expansion and FCF improvement.
• Pair trade: long GRFS / short a more China-exposed plasma or specialty-protein peer for the next 1-2 quarters; the relative edge is product mix and U.S./Europe demand insulation, while the short leg absorbs sector-wide reimbursement or pricing pressure.
• Avoid adding aggressively on the current print; wait for either a pullback after the post-earnings digestion or evidence that albumin pricing stabilizes, because the best risk/reward likely comes from confirmation rather than anticipation.
• If you already own GRFS, consider selling upside via covered calls 1-2 months out to monetize the likely range-bound tape while leverage keeps multiple expansion capped.
• Use a stop/tactical trim if the next update shows FCF slipping back negative or net leverage moving higher; with 4x+ leverage, the equity can de-rate quickly if the cash narrative weakens.